Examining the benefits of large-scale insurance mergers

Mergers of large health insurance companies have been in the news in recent months, but an editorial from Health Affairs suggests it remains to be seen if such deals are truly beneficial.

Paul von Ebers, president and CEO of Prospective Health, wrote the editorial, examining the recent mergers between Aetna and Humana; Anthem and Cigna; and Centene and Health Net.

“Many benefits of megamergers put forward by these companies will not materialize, and there will be few benefits for consumers,” von Ebers wrote. “Wall Street is understandably skeptical.”

Von Ebers explained that the reasons insurers give for making these massive deals can be broken down into three basic categories: scale economies, leverage in negotiations with hospitals and physicians, and diversification.

Are they legitimate reasons? When it comes to scale economies, von Ebers isn’t sold.

“Several studies of health insurers have found little or no economies of scale following mergers,” he wrote. “Studies in other industries suggest that even when economies of scale exist, the advantages dissipate with very large company sizes. Since administrative costs are a small portion of health insurance prices (10 to 15 percent, on average) it would take a large reduction in administrative costs to create a meaningful price reduction.”

Anthem and Cigna have published estimates of close to $2 billion in savings, von Ebers said, while also indicating no employees will be let go from either company. If $2 billion is really going to be saved in this instance, it may have less to do with economies of scale and more to do with other aspects of the deal.

When it comes to gaining leverage in negotiations, von Ebers noted that there is actually more to consider than meets the eye. Looking again at the Anthem/Cigna merger, he wrote that even if the new company isn’t forced to divest any Cigna businesses due to anti-trust worries, its market share still won’t necessarily make that large of a difference.

“I have had responsibility for provider negotiations in health plans with 35 percent, 60 percent, and 80 percent market share,” von Ebers wrote, referencing his own time working out deals in the insurance industry. “In my experience, a 60 percent market share plan does not always yield substantially lower pricing than a 35 percent share plan. Thus, Cigna’s impact on Anthem negotiations may not be great. Cigna customers will benefit from the lower prices Anthem already has, but Anthem customers won’t see much improvement.”

In the cases of Aetna’s acquisition of Humana and Centene’s acquisition of Health Net, von Ebers added, the total national volume would increase, so there would certainly be a benefit in future negotiations.

When it comes to that third category, von Ebers said some of these companies will see big benefits in terms of diversification. Centene, for instance, will be more stable thanks to Health Net’s commercial and Medicare business.

However, there is once again uncertainty related to the Anthem/Cigna merger.

“Anthem will bring expertise to Cigna in the individual market, but might not overcome the strength of local Blue Plans in non-Anthem states,” he wrote. “Cigna’s Medicaid business may improve Anthem’s position in this segment. Cigna brings behavioral health expertise through its Healthspring subsidiary. Compared to the significant benefits obtained by the other two mergers, these benefits are not game changing.”

The editorial concludes with a look at the uncertain future ahead. If costs rise over the next several years as CMS is projecting, does that throw any benefits gained from mergers completely out the window? Only time will tell.

The full text of Von Eber’s editorial can be found on the Health Affairs website.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.